Transdermal tulobuterol patch, a long-actingβ(2)-agonist.

Area of Science:

• Pharmacology
• Respiratory Medicine
• Drug Delivery Systems

Background:

• Tulobuterol patch (HokunalinTM Tape) is the first transdermal bronchodilator.
• It utilizes a beta(2)-adrenergic agonist for treating respiratory conditions.
• Existing treatments may have limitations in delivery timing and systemic side effects.

Purpose of the Study:

• To review the development rationale for the tulobuterol patch.
• To evaluate the clinical efficacy and safety of the tulobuterol patch in asthma and COPD.
• To examine patient treatment adherence with the tulobuterol patch.

Main Methods:

• Review of clinical data and evidence since the patch's approval in 1998.
• Analysis of pharmacokinetic properties related to respiratory function.
• Assessment of safety profiles and adverse event incidence.
• Evaluation of patient-reported adherence and ease-of-use data.

Main Results:

• The transdermal system optimizes drug concentration with morning respiratory function dips.
• The tulobuterol patch demonstrates clinical efficacy and safety in asthma and COPD.
• Once-daily application leads to good treatment adherence.
• Reduced incidence of systemic adverse reactions compared to other delivery methods.

Conclusions:

• The tulobuterol patch offers a safe and effective treatment option for asthma and COPD.
• Its innovative drug delivery system enhances therapeutic outcomes and patient compliance.
• The patch represents a significant advancement in transdermal bronchodilator therapy.